2021
COVID-19 vaccine – Long term immune decline and breakthrough infections
Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A, Abu-Sinni M, Shkeiri R, Elemy A, Hakim F. COVID-19 vaccine – Long term immune decline and breakthrough infections. Vaccine 2021, 39: 6984-6989. PMID: 34763949, PMCID: PMC8556595, DOI: 10.1016/j.vaccine.2021.10.038.Peer-Reviewed Original ResearchConceptsAntibody titersCOVID-19 vaccineBreakthrough infectionsSecond doseAntibody levelsPolymerase chain reactionBNT162b2 mRNA COVID-19 vaccineSARS-CoV-2 polymerase chain reactionMRNA COVID-19 vaccineStudy periodBreakthrough infection rateMedian antibody levelsMean antibody levelsLongitudinal prospective studyAntibody declineTiter elevationImmune declineProspective studyClinical indicationsMild casesHealthcare personnelInfection rateInfectionVaccinePeak levelsDirect antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term
Atamla M, Khoury J, Dabbah I, Kramsky R, Yaacob A, Veitsman E, Saadi T. Direct antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term. Clinical And Experimental Hepatology 2021, 7: 258-263. PMID: 34712826, PMCID: PMC8527337, DOI: 10.5114/ceh.2021.109192.Peer-Reviewed Original ResearchDirect antiviral agentsChronic hepatitis C virus (HCV) infectionHepatitis C virus infectionQuality of lifeC virus infectionHealth-related qualitySuccessful treatmentVirus infectionAntiviral agentsChronic HCV infectionDAA treatmentExtrahepatic manifestationsHCV infectionLiver diseaseLong termLiver fibrosisObservational studyProfound negative impactNew drugsInfectionHRQLTreatmentAverage timePatientsDrugs
2016
Severe Elevation of Liver Enzymes Does Not Necessarily Require Treatment Interruption in Patients Treated With a Combination of Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for HCV Infection
Saadi T, Khoury J. Severe Elevation of Liver Enzymes Does Not Necessarily Require Treatment Interruption in Patients Treated With a Combination of Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for HCV Infection. Journal Of Clinical Gastroenterology 2016, 50: 799. PMID: 27380458, DOI: 10.1097/mcg.0000000000000587.Commentaries, Editorials and LettersMeSH Keywords2-NaphthylamineAlanine TransaminaseAnilidesAntiviral AgentsAspartate AminotransferasesCarbamatesCyclopropanesDrug Therapy, CombinationFemaleHepatitis C, ChronicHumansLactams, MacrocyclicMacrocyclic CompoundsMiddle AgedProlineRibavirinRitonavirSulfonamidesUracilValineWithholding TreatmentPros and cons of circumcision: an evidence-based overview
Friedman B, Khoury J, Petersiel N, Yahalomi T, Paul M, Neuberger A. Pros and cons of circumcision: an evidence-based overview. Clinical Microbiology And Infection 2016, 22: 768-774. PMID: 27497811, DOI: 10.1016/j.cmi.2016.07.030.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHuman immunodeficiency virusRisk of infectionHigh human immunodeficiency virusSatisfaction of menRisk-benefit ratioHigh-quality evidenceInsertive anal intercourseEvidence-based overviewCons of circumcisionLack of harmHIV acquisitionSerious complicationsImmunodeficiency virusSexual functionSTI riskAdult circumcisionHigh prevalenceProtective effectAnal intercourseSterile settingsSmall studyMale partnersCircumcisionInfectionConflicting results